Exploring the etiology of Alzheimer disease using molecular genetics

JAMA

Volumn 277, Issue 10, 1997, Pages 825-831

  Lendon, Corinne L ^a   Ashall, Frank ^b   Goate, Alison M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BRAIN PROTEIN; PRESENILIN 1; PRESENILIN 2;

ALLELE; ALZHEIMER DISEASE; ARTICLE; CHROMOSOME 1; CHROMOSOME 14; CHROMOSOME 19; CHROMOSOME 21; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; HUMAN; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031057837     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.10.825     Document Type: Article

References (130)

1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34: 939-944.
2. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885-890.
3. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science. 1987;235:877-880.
4. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325: 733-736.
5. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 1987;235:880-884.
6. Robakis NK, Wisniewski HM, Jenkins EC, et al. Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet. 1987;1:384-385.
7. Lee VM-Y, Trojanowski JQ. Tau proteins and their significance in the pathobiology of Alzheimer's disease. In: Goate A, Ashall F, eds. Pathobiology of Alzheimer's Disease. London, United Kingdom: Academic Press; 1995:41-58.
8. Wang J-Z, Grundke-Iqbal I, Iqbal K. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease. Nat Med. 1996;2:871-875.
9. David KL, Haroutunian V. Strategies for the treatment of AD. Neurology. 1993;43(suppl 4):S52-S55.
10. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
11. Morris JC. The neurology of aging: normal versus pathologic change. Geriatrics. 1991;46:47-54.
12. Breteler M, Claus J, van Duijn C, Launer L, Hofman A. Epidemiology of Alzheimer's disease. Epidemiol Rev. 1992;14:59-82.
13. van Duijn C. Epidemiology of the dementias: recent developments and new approaches. J Neurol Neurosurg Psychiatry. 1996;60:478-488.
14. Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer's type in the Framingham Study. Neurology. 1992;42:1115-1140.
15. Stern Y, Gurland B, Tatemichi TK, et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994;271:1004-1010.
16. Snowdon D, Kemper S, Mortimer J, et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: findings from the Nun Study. JAMA. 1996;275:528-532.
17. van Duijn C, Tanja T, Haaxma R, et al. Head trauma and the risk of Alzheimer's disease. Am J Epidemiol. 1992;135:775-782.
18. Nee LE, Polinsky RJ, Eldridge R, et al. A family with histologically confirmed Alzheimer's disease. Arch Neurol. 1983;40:203-208.
19. Haltia M, Viitanen M, Sulkava R, et al. Chromosome 14-encoded Alzheimer's disease: genetic and clinicopathologic description. Neurology. 1994;36:362-367.
20. Lampe TH, Bird TD, Nochlin D, et al. Phenotype of chromosome 14-linked Alzheimer's disease: genetic and clinicopathological description. Ann Neurol. 1994;34:368-378.
21. Mann DM, Yates PO, Marcyniuk B, Ravindra CR. The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol Appl Neurobiol. 1986;12:447-457.
22. St George-Hyslop PH, Tanzi RE, Polinsky RJ, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science. 1987;235: 885-890.
23. Schellenberg GD, Bird TD, Wijsman EM, et al. Absence of linkage of chromosome 21q21 markers to familial Alzheimer's disease. Science. 1988;241:1507-1510.
24. Pericak-Vance MA, Yamaoka LH, Haynes CS, et al. Genetic linkage studies in familial Alzheimer's disease. Exp Neurol. 1988;102:271-279.
25. Goate AM, Haynes AR, Owen MJ, et al. Predisposing locus for Akheimer's disease on chromosome 21. Lancet. 1989;1:352-355.
26. St George-Hyslop PH, Haines JL, Farrer LA, et al. Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature. 1990;347:194-197.
27. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704-706.
28. Chartier-Harlin MC, Crawford F, Houlden H, et al. Early onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature. 1991;353:844-846.
29. Hendriks L, van Duijn C, Cras P, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat Genet. 1992;1:218-221.
30. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat Genet. 1992;1:345-347.
31. Murrell J, Farlow M, Ghetti B, Benson M. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 1991; 254:97-99.
32. Hardy J. Genetic analyses of the presenilins in Alzheimer's disease. Presented at the 1997 Keystone Symposia: Molecular Mechanisms in Alzheimer's Disease; February 2, 1997; Tamarron, Colo.
33. Sorbi S, Nacmias B, Forleo P, et al. Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. Ann Neurol. 1995;38:124-127.
34. Sorbi S, Nacmias B, Forleo P, et al. Missense mutation of S182 gene in Italian families with early-onset Alzheimer's disease. Lancet. 1995;346:439.
35. Fidani L, Rooke K, Chartier-Harlin MC, et al. Screening for mutations in the open reading frame and promoter of the β-amyloid precursor protein gene in familial Alzheimer's disease: identification of a further family with APP717 Val→Ile. Hum Mol Genet. 1992;1:165-168.
36. Brooks W, Martins R, De Voecht J, et al. A mutation in codon 717 of the amyloid precursor protein gene in an Australian family with Alzheimer's disease. Neurosci Lett. 1995;199:183-186.
37. Campion D, Brice A, Hannequin D, et al. No founder effect in three novel Alzheimer's disease families with APP717 Val→Ile mutation. J Med Genet. 1996;33:661-664.
38. Karlinsky H, Vaula G, Haines JL, et al. Molecular and prospective phenotypic characterization of a pedegree with familial Alzheimer's disease and amissense mutation in codon 717 of the β-amyloid precursor protein gene. Neurology. 1992;42:1445-1453.
39. Naruse S, Igarashi S, Kobayashi H, et al. Missense mutation Val→Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease. Lancet. 1991;337:978-979.
40. Yoshioka K, Miki T, Katsuya T, Ogihara T, Sakaki Y. The 717Val→Ile substitution in amyloid precursor protein is associated with familial Alzheimer's disease regardless of ethnic groups. Biochem Biophys Res Commun. 1991;178:1141-1146.
41. Schellenberg GD, Anderson L, O'dahl S, et al. APP717, APP693, and PRIP gene mutations are rare in Alzheimer's disease. Am J Hum Genet. 1991;49: 511-517.
42. Tanzi R, Vaula G, Romano D, et al. Assessment of amyloid beta-protein pecursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet. 1992;51:273-282.
43. Mullan M, Tsuji S, Mild T, et al. Clinical comparison of Alzheimer's disease in pedigrees with codon 717 Val-Ile mutation in the amyloid precursor protein gene. Neurobiol Aging. 1993;14:407-419.
44. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice over-expressing V717F β-amyloid precursor protein. Nature. 1995;373:523-527.
45. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
46. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science. 1992;258: 668-671.
47. Van Broeckhoven C, Backhovens H, Cruts M, et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat Genet. 1992;2:335-339.
48. St George-Hyslop P, Haines J, Rogaev E, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet. 1992;2:330-334.
49. Mullan M, Houlden H, Windelspecht M, et al. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the α1-antichymotrypsin gene. Nat Genet. 1992;2:340-342.
50. Sherrington R, Rogaev E, Liang Y, et al. Cloning of a gene bearing mis-sense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754-760.
51. Van Broeckhoven C. Presenflins in Alzheimer's disease. Nat Genet. 1995;11:230-232.
52. Boteva K, Vitek M, Mitsuda H, et al. Mutation analysis of presenilin 1 gene in Alzheimer's disease. Lancet. 1996;347:130-131.
53. Campion D, Flaman J-M, Brice A, et al. Mutations of the presenilin 1 gene in families with early-onset Alzheimer's disease. Hum Mol Genet. 1995;4: 2373-2377.
54. Clark RF, Hutton M, Fuldner RA, et al. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet. 1995;11:219-222.
55. Cruts M, Backhovens H, Wang S-Y, et al. Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. Hum Mol Genet. 1995;4:2363-2371.
56. Hutton M, Busfield F, Wragg M, et al. Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. Neuroreport. 1996;7:801-805.
57. Perez-Tur J, Froelich S, Prihar G, et al. A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport. 1995;7:297-301.
58. Pflieger-Bruss S, Hanf V, Behnisch P, Hagenmaier H, Rune G. Familial Alzheimer's disease associated with S182 codon 286 mutation. Lancet. 1995; 346:1040.
59. Wasco W, Pettingell WP, Jondro PD, et al. Familial Alzheimer's chromosome 14 mutations. Nat Med. 1995;1:848.
60. Tanahashi H, Mitsunaga Y, Takahashi K, et al. Missense mutation of S182 gene in Japanese familial Alzheimer's disease. Lancet. 1995;346:440.
61. Doan A, Thinakaran G, Borchelt D, et al. Protein topology of presenilin. Neuron. 1996;17:1023-1030.
62. Li X, Greenwald I. Membrane topology of the C elegans SEL-12 presenilin. Neuron. 1996;17:1015-1021.
63. Levy-Lahad E, Wysman EM, Nemens E, et al. A familial Alzheimer's disease locus on chromosome 1. Science. 1995;269:970-973.
64. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269:973-977.
65. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995; 376:775-778.
66. Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet. 1996;5:985-988.
67. Prihar G, Fuldner RA, Perez-Tur J, et al. Structure and alternate splicing of the presenilin 2 gene. Neuroreport. 1996;7:1680-1684.
68. Tanzi RE, McClatchey AI, Lamberti ED, et al. Protease inhibitor domain encoded by an amyloid precursor mRNA associated with Alzheimer's disease. Nature. 1988;331:528-530.
69. Esch FS, Keim PS, Beattie EC, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990;248:1122-1124.
70. Sisodia S, Koo E, Beyreuther K, Unterbeck A, Price D. Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science. 1990;248:492-494.
71. Haass C, Schlossmacher M, Hung A, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322-325.
72. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature. 1992;359:325-327.
73. Anderson J, Chen Y, Kim K, Robakis N. An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence. J Neurochem. 1992; 59:2328-2331.
74. Smith RP, Higuchi DA, Broze GJJ. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science. 1990;248:1126-1128.
75. Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. Science. 1990;248:745-748.
76. Roch J, Shapiro P, Sundsmo M, et al. Bacterial expression, purification, and functional mapping of the amyloid beta/A4 protein precursor. J Biol Chem. 1992;267:2214-2221.
77. Schubert D, Jin L, Saitoh T, Cole G. The regulation of amyloid beta protein precursor secretion and its modulatory role in cell adhesion. Neuron. 1989;3:689-694.
78. Mattson M, Cheng B, Culwell A, et al. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein. Neuron. 1993;10:243-254.
79. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990;250:279-282.
80. Jarrett J, Berger E, Lansbury P. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32:4693-4697.
81. Dovey H, Suomesaari-Chrysler S, Lieberburg I, Sinha S, Kiem P. Cells with a familial Alzheimer's disease mutation produce authentic β-peptide. Neuroreport. 1993;4:1039-1042.
82. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid-β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
83. Duff K, Eckman C, Hutton M, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710-713.
84. Borchelt D, Thinakaran G, Eekman C, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005-1013.
85. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med. 1997;3: 67-72.
86. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron. 1994; 13:45-53.
87. Lemere C, Lopera F, Kosik K, et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med. 1996;2:1146-1150.
88. Mann D, Iwatsubo T, Cairns N, et al. Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: predominance of Aβ42(43). Ann Neurol. 1996;40:149-156.
89. Kovacs D, Fausett H, Page K, et al. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996;2:224-229.
90. Thinakaran G, Borchelt D, Lee M, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17:181-190.
91. Levitan D, Greenwald I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature. 1995; 377:351-354.
92. Levitan D, Doyle T, Brousseau D, et al. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1996;93:14940-14944.
93. Vito P, Lacana E, D'adamio L. Interfering with apoptosis: Ca2+-binding protein ALG-2 and Alzheimer's disease gene ALG3. Science. 1996;271:521-525.
94. Wolozin B, Iwasaki K, Vito P, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science. 1996; 274:1710-1712.
95. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci U S A. 1993;90:1977-1981.
96. van Duijn C, de Knijff P, Wehnert A, et al. Apolipoprotein ∈4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet. 1994;7: 74-77.
97. Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
98. Poirier J, Davignon J, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993;342:697-699.
99. Roses A. Apolipoprotein E affects the rate of Alzheimer disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol. 1994;53:429-437.
100. Osuntokun B, Sahota A, Ogunniyi A, et al. Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. Ann Neurol. 1995;38:463-465.
101. Maestre G, Orman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol. 1995;37:254-259.
102. Hendrie H, Hall K, Hui S, et al. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol. 1995;37:118-120.
103. Marder K, Maestre G, Cote L, et al. The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia. Neurology. 1994;44: 1330-1331.
104. Saunders A, Schmader K, Breitner J, et al. Apolipoprotein E ∈4 allele distributions in late onset Alzheimer's disease and in other amyloid forming diseases. Lancet. 1993;342:710-711.
105. Kawamata J, Tanaka S, Shimohama S, Ueda K, Kimura J. Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia. J Neurol Neurosurg Psychiatry. 1994;57: 1414-1416.
106. Isoe K, Urakami K, Sato K, Takahashi K. Apolipoprotein E in patients with dementia of the Alzheimer type and vascular dementia. Acta Neurol Scand. 1996;93:133-137.
107. Lippa C, Smith T, Saunders A, et al. Apolipoprotein E genotype and Lewy body disease. Neurology. 1995;45:97-103.
108. St Clair D, Norman J, Perry R, et al. Apolipoprotein E epsilon 4 allele frequency in patients with Lewy body disease. Neurosci Lett. 1994;176:45-46.
109. Gearing M, Mon H, Mirra S. Aβ-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol. 1996;39:395-399.
110. Corder E, Saunders A, Risch N, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180-183.
111. Chartier-Harlin M-C, Parfitt M, Legrain S, et al. Apolipoprotein E ∈4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994;3:569-574.
112. Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer's disease with ApoE e2. Lancet. 1994;343:1432-1433.
113. van Duijn C, de Knijff P, Wehnert A, et al. The apolipoprotein E e2 allele is associated with increased risk of early onset Alzheimer's disease and a reduced survival. Ann Neurol. 1995;37:605-610.
114. St George-Hyslop P, Crapper McLachlan D, Tuda T, et al. Alzheimer's disease and possible gene interaction. Science. 1994;263:537.
115. Hardy J, Houlden H, Collinge J, et al. Apolipoprotein E genotype and Alzheimer's disease. Lancet. 1993;342:737-738.
116. Van Broeckhoven C, Backhovens H, Cruts M, et al. APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. Neurosci Lett. 1994;169:179-180.
117. Poirier J, Delisle M, Quirion R, et al. Apolipoprotein ∈4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci U S A. 1995;92:12260-12264.
118. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology. 1995;45:555-557.
119. Katzman R, Galasko D, Saitoh T, et al. Apolipoprotein-∈4 and head trauma: synergistic or additive risks? Neurology. 1996;46:889-891.
120. Nicoll J, Roberts GW, Graham D. Apolipoprotein E 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med. 1995; 1:135-148.
121. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163-166.
122. Zhou Z, Smith J, Greengard P, Gandy S. Alzheimer amyloid-β peptide forms denaturant-resistant complex with type e3 but not type e4 isoform of native apolipoprotein E. Mol Med. 1996;2:175-180.
123. Strittmatter W, Weisgraber K, Huang D, et al. Binding of human apolipoprotein E to synthetic amyloid beta-peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:8098-8102.
124. Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated proteins α1-antichymotrypsinand apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature. 1994;372:92-94.
125. LaDu M, Falduto M, Manelli A, et al. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem, 1994;269:23403-23406.
126. Strittmatter W, Saunders A, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule associated protein tau: implications for Alzheimer's disease. Proc Natl Acad Sci U S A. 1994;91:11183-11186.
127. Nathan B, Bellosta S, Sanan D, et al. Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro. Science. 1994;264:850-852.
128. Holtzman D, Pitas R, Kilbridge J, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neunte outgrowth in a central nervous system-derived neuronal cell Une. Proc Natl Acad Sci U S A. 1995;92:9480-9484.
129. Miyata M, Smith J. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet. 1996;14:55-61.
130. LaDu M, Pederson T, Frail D, et al. Purification of ApoE attenuates isoform-specific binding to β-amyloid. J Biol Chem. 1995;270:9039-9042.